Prevalence of transmitted drug resistance mutations among patients infected with human immunodeficiency virus type 1 (HIV-1) in Henan Province, China

Liu, Jinjin; Zhang, Xiaohua; Hou, Mingjie; Wei, Shuguang; Ma, Jing; Xu, Lixia; Yang, Xuan; Sun, Yan; Liu, Chunli; Zhao, Qi; Huo, Yuqi

doi:10.1097/cm9.0000000000002523

Chinese Medical Journal

2022

DOI: 10.1097/cm9.0000000000002523

|View full text |Cite

Prevalence of transmitted drug resistance mutations among patients infected with human immunodeficiency virus type 1 (HIV-1) in Henan Province, China

Jinjin Liu¹,

Xiaohua Zhang

Mingjie Hou

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite1

Independent2

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genotypic drug resistance testing was performed as described previously. [ 1 , 2 ] DRMs and antiretroviral susceptibility were analyzed by submitting the identified sequences to the Stanford HIV-1 drug resistance database ( http://hivdb.stanford.edu/ ), which is updated periodically. Subtypes of HIV isolates were analyzed using the REGA HIV-1 Subtyping Tool ( http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/ ) based on the partial pol region, which was further validated via phylogenetic analysis.…”

mentioning

confidence: 99%

Drug resistance mutations among people living with HIV with treatment failure in Henan Province, China

Liu,

Chen,

Wei

et al. 2023

Chinese Medical Journal

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 99%

Drug resistance mutations among people living with HIV with treatment failure in Henan Province, China

Liu,

Chen,

Wei

et al. 2023

Chinese Medical Journal

Self Cite

View full text Add to dashboard Cite

Increased prevalence of pretreatment drug resistance mutations in treatment-naïve people living with HIV-1 in Henan Province, China (2022/23)

Liu,

Wang

et al. 2023

Infection, Genetics and Evolution

View full text Add to dashboard Cite

Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China

Liu,

Li,

Sun

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Although most people living with HIV (PLWH) receiving antiretroviral therapy (ART) achieve continuous viral suppression, some show detectable HIV RNA as low-level viremia (LLV) (50–999 copies/mL). Drug resistance mutations (DRMs) in PLWH with LLV is of particular concern as which may lead to treatment failure. In this study, we investigated the prevalence of LLV and LLV-associated DRMs in PLWH in Zhengzhou City, China. Of 3616 ART-experienced PLWH in a long-term follow-up cohort from Jan 2022 to Aug 2023, 120 were identified as having LLV. Of these PLWH with LLV, we obtained partial pol and integrase sequences from 104 (70 from HIV-1 RNA and 34 from proviral DNA) individuals. DRMs were identified in 44 individuals. Subtyping analysis indicated that the top three subtypes were B (48.08%, 50/104), CRF07_BC (31.73%, 33/104), and CRF01_AE (15.38%, 16/104). The proportions of nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs) associated DRMs were 23.83% (24/104), 35.58% (37/104), 5.77% (6/104), and 3.85% (4/104), respectively, which contributed to an overall prevalence of 42.31% (44/104). When analyzed by individual DRMs, the most common mutation(s) were V184 (18.27%, 19/104), followed by V179 (11.54%, 12/104), K103 (9.62%, 10/104), Y181 (9.62%, 10/104), M41 (7.69%, 8/104), and K65R (7.69%, 8/104). The prevalence of DRMs in ART-experienced PLWH with LLV is high in Zhengzhou City and continuous surveillance can facilitate early intervention and provision of effective treatment.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Prevalence of transmitted drug resistance mutations among patients infected with human immunodeficiency virus type 1 (HIV-1) in Henan Province, China

Cited by 3 publications

References 6 publications

Drug resistance mutations among people living with HIV with treatment failure in Henan Province, China

Drug resistance mutations among people living with HIV with treatment failure in Henan Province, China

Increased prevalence of pretreatment drug resistance mutations in treatment-naïve people living with HIV-1 in Henan Province, China (2022/23)

Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China

Contact Info

Product

Resources

About